COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru
Medwave · 2025
DOI: 10.5867/medwave.2025.02.2962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medwave, 2025. Verfasst von Yeisson Rivero-Moreno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina Interna, Montefiore Medical Center, New York, United States of America. Hauptthemen laut MEDLINE: COVID-19, Pulmonary Fibrosis, Hospitalization.
Abstract (Originalsprache)
Introduction
The emergency caused by the COVID-19 pandemic has passed, but we must study the potential sequelae left in the population. Cases of pulmonary fibrosis have been reported after severe COVID-19. However, the association between these factors has not been widely studied in Latin American countries, one of the regions most affected by the pandemic.
Methods
A case-control study was conducted to determine whether a history of hospitalization due to COVID-19 is a risk factor for developing pulmonary fibrosis. We compared patients with a radiological diagnosis of pulmonary fibrosis on high-resolution computed tomography (cases) with those without such findings (controls), conducted between March 2021 and June 2023 in a referral hospital in Lima, Peru.
Results
Among the total number of patients evaluated, the median age was 72 years, with a predominance of females (58.2%). 7.5% of patients with pulmonary fibrosis had a history of hospitalization due to COVID-19, compared to 6.1% in the control group (OR 1.24; 95% CI 0.65 to 2.36). The stratified analysis revealed a significant odds ratio for the group of patients with arterial hypertension (OR 5.9; 95% CI 1.28 to 27.34). The median follow-up after hospitalization for COVID-19 was 315.5 days.
Conclusions
Hospitalization due to COVID-19 was not a risk factor for developing pulmonary fibrosis one year after medical discharge, except in patients with hypertension. Evidence suggests that the prevalence of pulmonary fibrosis may decrease over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Medicina Interna, Montefiore Medical Center, New York, United States of America.
- Facultad de Medicina, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú.
- Facultad de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
- Departamento de Medicina Interna, Jacobi Medical Center, New York, United States of America.
- Facultad de Medicina, Universidad de Oriente, Barcelona, Venezuela.
ORCID-Profile: Yeisson Rivero-Moreno, Vanessa García-Gil, Andrea García-Nunes, Miguel Rivas-Pérez, Erinor Montero-Palma, Andrea Chávez-Contreras, Gino Ramírez-Calderón, Nelson Martínez-Merizalde, Antony Gonzales-Uribe, Estefhany Areyan-Gamboa, Kevin Morales-Cornieles, Rafael Lezama-Graterol
Zitieren
APA
Rivero-Moreno, Y., García-Gil, V., García-Nunes, A., Rivas-Pérez, M., Montero-Palma, E., Chávez-Contreras, A., Ramírez-Calderón, G., Martínez-Merizalde, N., Gonzales-Uribe, A., Areyan-Gamboa, E., Morales-Cornieles, K., & Lezama-Graterol, R. (2025). COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru. Medwave. https://doi.org/10.5867/medwave.2025.02.2962
Vancouver
Rivero-Moreno Y, García-Gil V, García-Nunes A, Rivas-Pérez M, Montero-Palma E, Chávez-Contreras A, et al. COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru. Medwave. 2025. doi:10.5867/medwave.2025.02.2962
BibTeX
@article{RiveroMoreno2025,
author = {Rivero-Moreno, Yeisson and García-Gil, Vanessa and García-Nunes, Andrea and Rivas-Pérez, Miguel and Montero-Palma, Erinor and Chávez-Contreras, Andrea and Ramírez-Calderón, Gino and Martínez-Merizalde, Nelson and Gonzales-Uribe, Antony and Areyan-Gamboa, Estefhany and Morales-Cornieles, Kevin and Lezama-Graterol, Rafael},
title = {COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru},
journal = {Medwave},
year = {2025},
doi = {10.5867/medwave.2025.02.2962}
}
EUVIMED